Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

* Diagnosis of malignant disease
* No prior chemotherapy and scheduled to receive HEC (either cisplatin-containing regimen or anthracycline + cyclophosphamide \[AC\])

  * Cisplatin at a dose of ≥70mg/m\^2, with or without other chemotherapy agent(s) OR
  * Anthracycline (60 mg/m\^2) plus cyclophosphamide(600 mg/m\^2)
* Age ≥18 years
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2
* Required Initial Laboratory Values ≤ 120 days prior to registration

  * Serum Creatinine ≤2.0 mg/dL
  * Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic oxaloacetic transaminase (SGPT) ≤3 x Upper Limit of Normal (ULN)
  * Absolute neutrophil count (ANC) ≥1500/mm\^3
* No nausea or vomiting ≤ 24 hours prior to registration
* Negative pregnancy test (serum or urine) done ≤7 days prior to registration, for women of childbearing potential only (per clinician discretion)
* No severe cognitive compromise
* No known history of CNS disease (e.g. brain metastases, seizure disorder)
* No treatment with another antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone ≤30 days prior to registration or planned during protocol therapy
* No chronic phenothiazine administration as an antipsychotic agent (patients may receive prochlorperazine and other phenothiazines as rescue anti-emetic therapy)
* No concurrent use of amifostine
* No concurrent abdominal radiotherapy
* No concurrent use of quinolone antibiotic therapy
* No chronic alcoholism (as determined by the investigator)
* No known hypersensitivity to olanzapine
* No known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the previous six months.
* No history of uncontrolled diabetes mellitus (e.g. on insulin or an oral hypoglycemic agent)